SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
InterMune (nasdaq)ITMN
An SI Board Since March 2000
Posts SubjectMarks Bans Symbol
508 36 0 ITMN
Emcee:  Secret_Agent_Man Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
408>>NEW YORK, March 31 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITtuck-4/1/2004
407>>BRISBANE, Calif., March 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Natuck-3/30/2004
406>>DEERFIELD, Ill., and BRISBANE, Calif., March 29 /PRNewswire-FirstCall/ -tuck-3/29/2004
405[Pirfenidone granted Orphan Drug Designation] >>BRISBANE, Calif., March 2tuck-3/24/2004
404Press Release Source: CoTherix, Inc. James Pennington, M.D., Joins CoTherix Inrkrw-2/11/2004
403>>BRISBANE, Calif., Feb. 11 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nastuck-2/11/2004
402>>BRISBANE, Calif., Feb. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdtuck-2/9/2004
401>>BRISBANE, Calif., Jan. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nastuck-1/29/2004
400I gather good results were not expected in this liver fibrosis trial, as the stotuck-1/21/2004
399The slant of the article is fairly negative (no stat. significant effect etc.) -Biomaven-1/7/2004
398>>BRISBANE, Calif., Jan. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdtuck-1/7/2004
397<i>How big is a two log reduction in percentages?</i> It's baseBiomaven-12/18/2003
396The PR does not say but the non-responders should be nearly all genotype 1 sinceIRWIN JAMES FRANKEL-12/17/2003
395Pretty good results considering these patients had flunked the best treatment cuMichael Young-12/16/2003
394Bingo I have followed HCV for a long time. I knew ITMN was doing this study buIRWIN JAMES FRANKEL-12/16/2003
393InterMune Announces Presentation of Interim Findings of the First Clinical ExperIRWIN JAMES FRANKEL-12/16/2003
392>>BRISBANE, Calif., Dec. 16 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nastuck-12/16/2003
391ITMN off in the premarket on Oritavancin delay: >>7:11AM InterMune NDA fotuck-11/21/2003
390ITMN beats estimates by about 30 cents, guides revenue at lower end of range, butuck-10/31/2003
389>>BOSTON, Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN tuck-10/29/2003
388>>BRISBANE, Calif., Oct. 22 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nastuck-10/23/2003
387InterMune Announces Executive Management Changes Thursday September 25, 8:12 am IRWIN JAMES FRANKEL-9/25/2003
386Full article at: Message 19313710 PeterBiomaven-9/17/2003
38507:26 ET ITMN InterMune's Infergen showing promising results in battling IRWIN JAMES FRANKEL-9/17/2003
384InterMune and Joseph L. Stendig Announce Settlement of Lawsuit BONITA SPRINGS,rkrw-9/6/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News